The U.S. Federal Trade Commission is closely monitoring the pharmaceutical industry for potential anticompetitive practices, as some of the blockbuster drugs are nearing the end of their patent ...
PHILADELPHIA, March 17 (Reuters) - The U.S. Federal Trade Commission is on the lookout for anticompetitive practices in the pharmaceutical industry with a number of blockbuster drugs ‌near the end of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results